logo
logo

Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs

Jan 11, 2021•over 4 years ago

Amount Raised

$190 Million

Round Type

series b

LexingtonArtificial IntelligenceBiotechnologyHealth Care

Description

Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changing drugs, closed a $190 million Series B financing and unveiled select therapeutic programs. Valo will further discuss these programs at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:20 PM EST (link below).

Company Information

Company

Valo

Location

Lexington, Massachusetts, United States

About

Valo is a technology company built to transform drug discovery and development using large-scale data and AI-powered computation. Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The company’s Opal Com­pu­ta­tion­al Plat­form™ is an end-to-end drug dis­cov­ery and devel­op­ment plat­form with a uni­fied archi­tec­ture designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams, ini­tial­ly focused on car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech